Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation

Haematologica

Volumn 87, Issue 9, 2002, Pages 1003-1005

  Gómez, Marta ^a   Urbano Ispizua, Alvaro ^a   Cervantes, Francisco ^a   Fernández Avilés, Francesc ^a   Rovira, Montserrat ^a   Carreras, Enric ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Allogeneic stem cell transplantation; Chronic myeloid leukemia; Donor lymphocyte infusions; Relapse

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE TRANSFUSION; MALE; RELAPSE; REMISSION; STEM CELL TRANSPLANTATION;

HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE TRANSFUSION; RECURRENCE; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036740878     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronicbw6 myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-8.
2. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100:397-405.
3. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusions for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
4. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19:927-32.
5. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer De, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-6.
6. Novitzky N, Rubinstein R, Hallet JM, du Toit CE, Thomas VL. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Transplantation 2000; 69:1358:63.
7. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82:2310-5.
8. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemic reaction without graft-versus-host disease. Bone Marrow Transplant 1993; 11:329-36.
9. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12:125-30.
10. Bar BM, Schattenberg A, Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11:513-6.